COVID-19 Can Exacerbate Pattern Hair Loss and Trigger Telogen Effluvium: The Role of Proteoglycan Replacement Therapy with Nourkrin in Clinical Treatment of COVID-19 Associated Hair Loss

The document discusses the increased occurrence of pattern hair loss (PHL) and telogen effluvium (TE) in COVID-19 patients, possibly due to stress, inflammation, and oxidative stress. It suggests that the reduction of proteoglycans, which regulate hair growth, could be a link between hair loss and COVID-19. The paper explores the use of proteoglycan replacement therapy (PRT) using Nourkrin® with Marilex® to address this issue in COVID-19 patients. Nourkrin® is a hair loss treatment that has anti-inflammatory and hair growth normalizing effects, and it has been shown to suppress several proinflammatory cytokines. Therefore, PRT is a potential treatment option for new-onset or aggravated PHL in COVID-19 survivors. The document concludes that Nourkrin® can be considered a safe treatment to prevent and treat COVID-19 related PHL and TE, but further clinical investigation is needed.